Objective: Persistent microalbuminuria is earliest indicator of Chronic Kidney Disease amongst hypertensive patients and is also associated with target organ damage resulting in stroke, retinopathy and adverse cardiovascular outcomes. The present study was aimed to evaluate the reduction in microalbuminuria amongst uncontrolled essential hypertensive patients with use of triple combination therapy. Design and method: It was a hospital based cross sectional prospective study done on 50 essential hypertension patients having uncontrolled blood pressure and presence of microalbuminuria in urine. Total duration of therapy was 3 months and triple combination therapy used in study as antihypertensive was Triplixam (Perindopril 4 mg, Amlodipine 5 mg and Indapamide 1.25 mg). Patients having Diabetes and other co morbidities were excluded from the study. Patients were evaluated at baseline and end of study visit for SBP,DBP, Urine for albumin excretion. Ethical clearance was taken prior to inclusion of patients. Results: There was significant reduction in both SBP (18 mm Hg) and DBP (10 mm Hg) with use of triple combination therapy (Triplixam). Microalbuminuria turned to normal albumin excretion in urine that was statistically significant (p < 0.01) was most significant and convincing finding. Conclusions: Triplixam is an excellent triple agent that can reduce blood pressure promptly and bring about reduction in urine albumin excretion thereby decreasing risk of end target organ damage. Early detection of renal dysfunction through microalbuminuria and prompt treatment can confer future protection from end stage renal disease.